Elsevier, a world-leading provider of scientific, technical and medical information products and services, and the Federation of Biochemical Societies (FEBS) announced today the launch of FEBS Open Bio, an open access journal. The journal is dedicated to publishing articles across the molecular and cellular life sciences in both health and disease.
In launching this new journal, FEBS and Elsevier serve authors who have an interest in a fast publishing process. The journal is open to direct submissions of novel findings. It is also open to the transfer of articles submitted to existing FEBS publications (FEBS Letters, FEBS Journal and Molecular Oncology), which have been judged as sound and a contribution to knowledge, but do not meet the criteria set by the editors for publication in these journals. These manuscripts can now proceed for publication in FEBS Open Bio with their original reviewer reports, without the need to resubmit or reformat the manuscript.
Felix Go-i, Chairman of the FEBS publication committee says, "As a society aimed at advancing science we do understand that the needs of the community change over time. Launching FEBS Open Bio is the result of listening to the scientists we serve. We are very happy that many of the editors of existing FEBS journals are actively supporting this new launch and have joined the editorial board of FEBS Open Bio."
Carl Schwarz, Publishing Director Elsevier Life Sciences said, "We are delighted that we have been able to expand our collaboration with FEBS by launching a new journal that will certainly benefit the scientific community. The launch of FEBS Open Bio is yet another milestone in our continuous collaboration with FEBS."